Page last updated: 2024-10-18

glycine and Melanoma

glycine has been researched along with Melanoma in 28 studies

Melanoma: A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445)

Research Excerpts

ExcerptRelevanceReference
"N-Diazoacetyl derivatives of glycine and phenylalanine show antitumor activity in mice bearing P388 leukemia or B16 melanoma."7.66Antitumor activity of N-diazoacetyl derivatives of glycine and phenylalanine against P388 leukemia and B16 melanoma in mice. ( Baldini, L; Giraldi, T; Sava, G, 1982)
"Malignant melanoma is a highly aggressive tumor resistant to chemotherapy."5.46Poly(N-phenylglycine)-Based Nanoparticles as Highly Effective and Targeted Near-Infrared Photothermal Therapy/Photodynamic Therapeutic Agents for Malignant Melanoma. ( Guo, XL; Jiang, BP; Liang, H; Shen, XC; Wang, Y; Zhang, L; Zhu, Y, 2017)
" Our objective was to precisely assess changes in α-syn levels in human neuroblastoma (SH-SY5Y) and melanoma (SK-MEL-2) cell lines following acute exposure to pesticides (rotenone, paraquat, maneb, and glyphosate) using Western blot and flow cytometry."3.79Specific pesticide-dependent increases in α-synuclein levels in human neuroblastoma (SH-SY5Y) and melanoma (SK-MEL-2) cell lines. ( Andrieu, T; Baron, T; Bétemps, D; Chorfa, A; Hogeveen, K; Lazizzera, C; Morignat, E, 2013)
"N-Diazoacetyl derivatives of glycine and phenylalanine show antitumor activity in mice bearing P388 leukemia or B16 melanoma."3.66Antitumor activity of N-diazoacetyl derivatives of glycine and phenylalanine against P388 leukemia and B16 melanoma in mice. ( Baldini, L; Giraldi, T; Sava, G, 1982)
"Glycine has been well characterized in spinal cord as an inhibitory neurotransmitter which activates a glycine-gated chloride channel (GlyR) expressed in postsynaptic membranes."2.40Glycine: a new anti-inflammatory immunonutrient. ( Bradford, B; Enomoto, N; Ikejema, K; Rose, ML; Rusyn, I; Schemmer, P; Seabra, V; Stacklewitz, RF; Thurman, RG; Wheeler, MD; Yin, M; Zhong, Z, 1999)
"Malignant melanoma is a highly aggressive tumor resistant to chemotherapy."1.46Poly(N-phenylglycine)-Based Nanoparticles as Highly Effective and Targeted Near-Infrared Photothermal Therapy/Photodynamic Therapeutic Agents for Malignant Melanoma. ( Guo, XL; Jiang, BP; Liang, H; Shen, XC; Wang, Y; Zhang, L; Zhu, Y, 2017)
"Six CDKN2A families had pancreatic cancer."1.31Genotype-phenotype relationships in U.S. melanoma-prone families with CDKN2A and CDK4 mutations. ( Chidambaram, A; Fraser, MC; Goldstein, AM; Struewing, JP; Tucker, MA, 2000)
"Recently, four cancer-associated mutants of the A-alpha subunit have been described: Glu64-->Asp in lung carcinoma, Glu64-->Gly in breast carcinoma, Arg418-->Trp in melanoma, and Delta171 - 589 in breast carcinoma."1.31Disruption of protein phosphatase 2A subunit interaction in human cancers with mutations in the A alpha subunit gene. ( Pham, HT; Ruediger, R; Walter, G, 2001)
"The putative metastasis suppressor genes, NME1(nm23-1) and NME2(nm23-2), were examined in a model system we developed to approximate the dissemination of melanoma from a primary skin tumor."1.29Differential expression and mutation of NME genes in autologous cultured human melanoma cells with different metastatic potentials. ( Backer, JM; Hamby, CV; Mendola, CE; Potla, L; Stafford, G, 1995)
"Many BRMs have been used in treatment of melanoma, e."1.28Current status of melanoma treatment with interferon, cytokines and other biologic response modifiers in Japan. ( Hayasaka, K; Ishihara, K; Yamazaki, N, 1989)

Research

Studies (28)

TimeframeStudies, this research(%)All Research%
pre-19906 (21.43)18.7374
1990's5 (17.86)18.2507
2000's3 (10.71)29.6817
2010's12 (42.86)24.3611
2020's2 (7.14)2.80

Authors

AuthorsStudies
Zhang, H1
Liu, X1
Chen, Y1
Xu, R1
He, S1
Pizzato Scomazzon, S1
Riccio, A1
Santopolo, S1
Lanzilli, G1
Coccia, M1
Rossi, A1
Santoro, MG1
Yan, C1
Saleh, N1
Yang, J2
Nebhan, CA1
Vilgelm, AE1
Reddy, EP1
Roland, JT1
Johnson, DB1
Chen, SC1
Shattuck-Brandt, RL1
Ayers, GD1
Richmond, A1
Saei, A1
Palafox, M1
Benoukraf, T1
Kumari, N1
Jaynes, PW1
Iyengar, PV1
Muñoz-Couselo, E1
Nuciforo, P1
Cortés, J1
Nötzel, C1
Kumarakulasinghe, NB1
Richard, JLC1
Bin Adam Isa, ZF1
Pang, B1
Guzman, M1
Siqin, Z1
Yang, H1
Tam, WL1
Serra, V1
Eichhorn, PJA1
Mu, LM1
Liu, L1
Liu, R1
Du, YF1
Luo, Q1
Xu, JR1
Xie, Y1
Lu, WL1
Chorfa, A1
Bétemps, D1
Morignat, E1
Lazizzera, C1
Hogeveen, K1
Andrieu, T1
Baron, T1
Fortes, C1
Mastroeni, S1
Segatto M, M1
Hohmann, C1
Miligi, L1
Bakos, L1
Bonamigo, R1
Cheewinthamrongrod, V1
Kageyama, H1
Palaga, T1
Takabe, T1
Waditee-Sirisattha, R1
Suarez-Kelly, LP1
Kemper, GM1
Duggan, MC1
Stiff, A1
Noel, TC1
Markowitz, J1
Luedke, EA1
Yildiz, VO1
Yu, L1
Jaime-Ramirez, AC1
Karpa, V1
Zhang, X1
Carson, WE1
Muqaku, B1
Eisinger, M1
Meier, SM1
Tahir, A1
Pukrop, T1
Haferkamp, S1
Slany, A1
Reichle, A1
Gerner, C1
Jiang, BP1
Zhang, L1
Guo, XL1
Shen, XC1
Wang, Y1
Zhu, Y1
Liang, H1
Venè, R1
Castellani, P1
Delfino, L1
Lucibello, M1
Ciriolo, MR1
Rubartelli, A1
Miao, Y1
Jalili, A1
Wagner, C1
Pashenkov, M1
Pathria, G1
Mertz, KD1
Widlund, HR1
Lupien, M1
Brunet, JP1
Golub, TR1
Stingl, G1
Fisher, DE1
Ramaswamy, S1
Wagner, SN1
Yamashina, S1
Ikejima, K1
Rusyn, I2
Sato, N1
Sava, G1
Giraldi, T1
Baldini, L1
Thomasset, N1
Quash, GA1
Doré, JF1
Hamby, CV1
Mendola, CE1
Potla, L1
Stafford, G1
Backer, JM1
Kask, K1
Berthold, M1
Kahl, U1
Nordvall, G1
Bartfai, T1
Ts'ao, C1
Molteni, A1
Taylor, JM1
Rose, ML2
Madren, J1
Bunzendahl, H1
Thurman, RG2
Goldstein, AM1
Struewing, JP1
Chidambaram, A1
Fraser, MC1
Tucker, MA1
Wheeler, MD1
Ikejema, K1
Enomoto, N1
Stacklewitz, RF1
Seabra, V1
Zhong, Z1
Yin, M1
Schemmer, P1
Bradford, B1
Ruediger, R1
Pham, HT1
Walter, G1
Ishihara, K1
Hayasaka, K1
Yamazaki, N1
Knudsen, BS1
Harpel, PC1
Nachman, RL1
Pasztor, LM1
Hu, F1
Stankova, L1
Bigley, R1
Schulman, JD1
Wrathall, JR1
Silagi, S1
Doores, L1

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
[NCT01205815]3,000 participants (Anticipated)Observational2010-06-03Recruiting
Evaluation of the Capability of a Glycine Oral Supplement for Diminishing Bronchial Inflammation in Children With Cystic Fibrosis[NCT01417481]Phase 213 participants (Actual)Interventional2012-03-31Terminated (stopped due to Some of the researchers finished their participation in the study.)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Changes in Serum Concentration of Inflammatory Biomarkers (TNF-alpha)

To correct for the baseline variability, all measurements were expressed as percentage of baseline (value at week 8 with respect to baseline value [beginning of the glycine or placebo period, respectively]). Then, percentages were log-transformed to adjust to a normal distribution. (NCT01417481)
Timeframe: 8 weeks

Interventionlog (percent change) (Mean)
Glycine-0.3908
Placebo0.2035

Changes in Sputum Concentration of Inflammatory Biomarkers (G-CSF)

To correct for the baseline variability, all measurements were expressed as percentage of baseline (value at week 8 with respect to baseline value [beginning of the glycine or placebo period, respectively]). Then, percentage change was log-transformed to adjust to a normal distribution. (NCT01417481)
Timeframe: 8 weeks

Interventionlog (percent change) (Mean)
Glycine-0.0819
Placebo0.1668

Changes in Sputum Concentration of Inflammatory Biomarkers (IL-6)

To correct for the baseline variability, all measurements were expressed as percentage of baseline (value at week 8 with respect to baseline value [beginning of the glycine or placebo period, respectively]). Then, percentage change was log-transformed to adjust to a normal distribution. (NCT01417481)
Timeframe: 8 weeks

Interventionlog (percent change) (Mean)
Glycine-0.00007
Placebo0.1739

Changes in Clinical Data Scores (Other Than Sputum Production, Dyspnea and Global Symptoms)

"To correct for the baseline variability, all measurements were expressed as percentage of baseline (value at week 8 with respect to baseline value [beginning of the glycine or placebo period, respectively]).~Each respiratory symptom (Cough severity, Sputum features, Appetite, Dyspnea, and Energy perception) was evaluated in a 5-options Likert scale, ranging from 1 (better) to 5 (worse). The total score was computed by the simple sum of the five symptoms." (NCT01417481)
Timeframe: 8 weeks

,
InterventionPercentage of baseline (Mean)
Cough questionnaire scoreAppetite questionnaire scoreEnergy questionnaire scoreBody weightHeightHeart rateRespiratory rateTemperature
Glycine81.189.184.6101.6100.5103.594.8100.0
Placebo89.1132.1111.5103.6100.598.1109.0100.1

Changes in FEV1, FEF25, and FEFmax

To correct for the baseline variability, all measurements were expressed as percentage of baseline (value at week 8 with respect to baseline value [beginning of the glycine or placebo period, respectively]). (NCT01417481)
Timeframe: 8 weeks

,
InterventionPercentage of baseline (Mean)
Forced expiratory volume at first second (FEV1)Forced expiratory flow at 25%FVC (FEF25)Maximal forced expiratory flow (FEFmax, PEFR)
Glycine109.7133.9115.3
Placebo91.483.391.2

Changes in Other Spirometric Variables

To correct for the baseline variability, all measurements were expressed as percentage of baseline (value at week 8 with respect to baseline value [beginning of the glycine or placebo period, respectively]). (NCT01417481)
Timeframe: 8 weeks

,
InterventionPercentage of baseline (Mean)
Forced vital capacity (FVC)Forced expiratory flow at 75%FVC (FEF75)
Glycine104.1111.8
Placebo100.6108.9

Changes in Pulse Oximetry, FEV1/FVC, and FEF50.

To correct for the baseline variability, all measurements were expressed as percentage of baseline (value at week 8 with respect to baseline value [beginning of the glycine or placebo period, respectively]). (NCT01417481)
Timeframe: 8 weeks

,
InterventionPercentage of baseline (Mean)
Peripheral oxygen saturation (SpO2)FEV1/FVCForced expiratory flow at 50%FVC (FEF50)
Glycine105.2105.2115.5
Placebo98.994.993.1

Changes in Score for Sputum Production, Dyspnea and Global Symptoms

"To correct for the baseline variability, all measurements were expressed as percentage of baseline (value at week 8 with respect to baseline value [beginning of the glycine or placebo period, respectively]).~In the symptoms questionnaire, each respiratory symptom (Cough severity, Sputum features, Appetite, Dyspnea, and Energy perception) was evaluated in a 5-options Likert scale, ranging from 1 (better) to 5 (worse). The total score was computed by the simple sum of the five symptoms." (NCT01417481)
Timeframe: 8 weeks

,
InterventionPercentage of baseline (Mean)
Sputum questionnaire scoreDyspnea questionnaire scoreTotal questionnaire score
Glycine82.075.677.7
Placebo102.6103.898.7

Changes in Serum Concentration of Inflammatory Biomarkers (Other Than TNF-alpha)

To correct for the baseline variability, all measurements were expressed as percentage of baseline (value at week 8 with respect to baseline value [beginning of the glycine or placebo period, respectively]). Then, percentages were log-transformed to adjust to a normal distribution. (NCT01417481)
Timeframe: 8 weeks

,
Interventionlog (percent change) (Mean)
MyeloperoxidaseIL-1IL-4IL-6IL-7IL-8IL-12IL-13G-CSFIFN-gammaMCP-1MIP-1beta
Glycine-0.4361-0.16350.29640.00850.0356-0.14660.3203-0.0561-0.07760.3272-0.08360.0330
Placebo-0.2906-0.03520.14700.22550.0819-0.23640.26030.19530.22720.36390.0472-0.0608

Changes in Sputum Concentration of Inflammatory Biomarkers (Other Than IL-6 and G-CSF)

To correct for the baseline variability, all measurements were expressed as percentage of baseline (value at week 8 with respect to baseline value [beginning of the glycine or placebo period, respectively]). Then, percentage change was log-transformed to adjust to a normal distribution. (NCT01417481)
Timeframe: 8 weeks

,
Interventionlog (percent change) (Mean)
MyeloperoxidaseIL-1IL-2IL-4IL-5IL-7IL-8IL-10IL-12IL-13IL-17IFN-gammaMCP-1MIP-1betaTNF-alphaGM-CSF
Glycine0.1294-0.09180.0233-0.01610.24980.0611-0.08240.05490.16750.16300.06800.02480.0042-0.03030.0412-0.0538
Placebo0.0669-0.0102-0.02740.05220.13040.13870.05420.00740.06770.09530.11400.06490.26080.09770.1568-0.0822

Reviews

1 review available for glycine and Melanoma

ArticleYear
Glycine: a new anti-inflammatory immunonutrient.
    Cellular and molecular life sciences : CMLS, 1999, Nov-30, Volume: 56, Issue:9-10

    Topics: Alcohols; Animals; Anti-Inflammatory Agents; Calcium Channels, L-Type; Chloride Channels; Cyclospori

1999

Other Studies

27 other studies available for glycine and Melanoma

ArticleYear
KDOAM-25 Overcomes Resistance to MEK Inhibitors by Targeting KDM5B in Uveal Melanoma.
    BioMed research international, 2022, Volume: 2022

    Topics: Annexins; Cell Line, Tumor; Cell Proliferation; Epigenesis, Genetic; Glycine; Histones; Humans; Jumo

2022
The Zinc-Finger AN1-Type Domain 2a Gene Acts as a Regulator of Cell Survival in Human Melanoma: Role of E3-Ligase cIAP2.
    Molecular cancer research : MCR, 2019, Volume: 17, Issue:12

    Topics: Baculoviral IAP Repeat-Containing 3 Protein; Boron Compounds; Bortezomib; Cell Line, Tumor; Cell Tra

2019
Novel induction of CD40 expression by tumor cells with RAS/RAF/PI3K pathway inhibition augments response to checkpoint blockade.
    Molecular cancer, 2021, 06-06, Volume: 20, Issue:1

    Topics: Animals; Antineoplastic Agents; CD40 Antigens; Female; Glycine; Humans; Immune Checkpoint Inhibitors

2021
Loss of USP28-mediated BRAF degradation drives resistance to RAF cancer therapies.
    The Journal of experimental medicine, 2018, 07-02, Volume: 215, Issue:7

    Topics: Animals; Apoptosis; Cell Line, Tumor; Down-Regulation; Drug Resistance, Neoplasm; F-Box-WD Repeat-Co

2018
Nanostructured SL9-CpG Lipovaccines Elicit Immune Response for the Treatment of Melanoma.
    International journal of molecular sciences, 2019, May-05, Volume: 20, Issue:9

    Topics: Animals; Cancer Vaccines; Cytokines; Disease Models, Animal; Female; Glycine; Humans; Immunomodulati

2019
Specific pesticide-dependent increases in α-synuclein levels in human neuroblastoma (SH-SY5Y) and melanoma (SK-MEL-2) cell lines.
    Toxicological sciences : an official journal of the Society of Toxicology, 2013, Volume: 133, Issue:2

    Topics: alpha-Synuclein; Cell Death; Cell Line, Tumor; Cell Survival; Glycine; Glyphosate; Humans; Insectici

2013
Occupational Exposure to Pesticides With Occupational Sun Exposure Increases the Risk for Cutaneous Melanoma.
    Journal of occupational and environmental medicine, 2016, Volume: 58, Issue:4

    Topics: Adult; Aged; Brazil; Case-Control Studies; Female; Fungicides, Industrial; Glycine; Glyphosate; Herb

2016
DNA damage protecting and free radical scavenging properties of mycosporine-2-glycine from the Dead Sea cyanobacterium in A375 human melanoma cell lines.
    Journal of photochemistry and photobiology. B, Biology, 2016, Volume: 164

    Topics: Antioxidants; Cell Line, Tumor; Cyanobacteria; Cyclohexanols; DNA Damage; Free Radical Scavengers; G

2016
The combination of MLN2238 (ixazomib) with interferon-alpha results in enhanced cell death in melanoma.
    Oncotarget, 2016, Dec-06, Volume: 7, Issue:49

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; B

2016
Multi-omics Analysis of Serum Samples Demonstrates Reprogramming of Organ Functions Via Systemic Calcium Mobilization and Platelet Activation in Metastatic Melanoma.
    Molecular & cellular proteomics : MCP, 2017, Volume: 16, Issue:1

    Topics: Asparagine; Biomarkers, Tumor; Blood Platelets; Cachexia; Calcium; Glycine; Humans; Melanoma; Metabo

2017
Poly(N-phenylglycine)-Based Nanoparticles as Highly Effective and Targeted Near-Infrared Photothermal Therapy/Photodynamic Therapeutic Agents for Malignant Melanoma.
    Small (Weinheim an der Bergstrasse, Germany), 2017, Volume: 13, Issue:8

    Topics: Animals; Cell Death; Cell Line, Tumor; Glycine; Humans; Hyaluronic Acid; Hyperthermia, Induced; Infr

2017
The cystine/cysteine cycle and GSH are independent and crucial antioxidant systems in malignant melanoma cells and represent druggable targets.
    Antioxidants & redox signaling, 2011, Nov-01, Volume: 15, Issue:9

    Topics: Antioxidants; Arsenic Trioxide; Arsenicals; Blotting, Western; Buthionine Sulfoximine; Cell Survival

2011
Substitution of Gly with Ala enhanced the melanoma uptake of technetium-99m-labeled Arg-Ala-Asp-conjugated alpha-melanocyte stimulating hormone peptide.
    Bioorganic & medicinal chemistry letters, 2012, Feb-15, Volume: 22, Issue:4

    Topics: alpha-MSH; Animals; Binding, Competitive; Cell Line, Tumor; Glycine; Inhibitory Concentration 50; Me

2012
Dual suppression of the cyclin-dependent kinase inhibitors CDKN2C and CDKN1A in human melanoma.
    Journal of the National Cancer Institute, 2012, Nov-07, Volume: 104, Issue:21

    Topics: Animals; Antineoplastic Agents; Aspartic Acid; Benzamides; Blotting, Western; Cell Line, Tumor; Cycl

2012
Glycine as a potent anti-angiogenic nutrient for tumor growth.
    Journal of gastroenterology and hepatology, 2007, Volume: 22 Suppl 1

    Topics: Calcium; Cell Movement; Chloride Channels; Endothelium, Vascular; Glycine; Humans; In Vitro Techniqu

2007
Antitumor activity of N-diazoacetyl derivatives of glycine and phenylalanine against P388 leukemia and B16 melanoma in mice.
    Cancer treatment reports, 1982, Volume: 66, Issue:1

    Topics: Animals; Antineoplastic Agents; Azo Compounds; Glycine; Leukemia, Experimental; Melanoma; Mice; Neop

1982
The differential contribution of arginase and transamidinase to ornithine biosynthesis in two achromic human melanoma cell lines.
    FEBS letters, 1982, Nov-01, Volume: 148, Issue:1

    Topics: Amidinotransferases; Arginase; Arginine; Cell Line; Glycine; Humans; Hydrogen-Ion Concentration; Mel

1982
Differential expression and mutation of NME genes in autologous cultured human melanoma cells with different metastatic potentials.
    Biochemical and biophysical research communications, 1995, Jun-15, Volume: 211, Issue:2

    Topics: Amino Acid Sequence; Animals; Base Sequence; Cell Line; Clone Cells; DNA Primers; Gene Expression; G

1995
Delineation of the peptide binding site of the human galanin receptor.
    The EMBO journal, 1996, Jan-15, Volume: 15, Issue:2

    Topics: Alanine; Amino Acid Sequence; Animals; Binding Sites; Cell Membrane; Cloning, Molecular; Conserved S

1996
Injury-specific cytotoxic response of tumor cells and endothelial cells.
    Pathology, research and practice, 1996, Volume: 192, Issue:1

    Topics: Animals; Cattle; Cells, Cultured; Chromium Radioisotopes; Endopeptidases; Endothelium, Vascular; Gly

1996
Dietary glycine inhibits the growth of B16 melanoma tumors in mice.
    Carcinogenesis, 1999, Volume: 20, Issue:5

    Topics: Animals; Cell Division; Cell Line; Diet; Glycine; Melanoma; Mice; Neovascularization, Pathologic; Sk

1999
Genotype-phenotype relationships in U.S. melanoma-prone families with CDKN2A and CDK4 mutations.
    Journal of the National Cancer Institute, 2000, Jun-21, Volume: 92, Issue:12

    Topics: Adolescent; Adult; Age Factors; Aged; Arginine; Aspartic Acid; Cyclin-Dependent Kinases; Cysteine; G

2000
Disruption of protein phosphatase 2A subunit interaction in human cancers with mutations in the A alpha subunit gene.
    Oncogene, 2001, Jan-04, Volume: 20, Issue:1

    Topics: Amino Acid Sequence; Arginine; Aspartic Acid; Breast Neoplasms; Female; Glutamic Acid; Glycine; Huma

2001
Current status of melanoma treatment with interferon, cytokines and other biologic response modifiers in Japan.
    The Journal of investigative dermatology, 1989, Volume: 92, Issue:5 Suppl

    Topics: Biological Factors; Biological Products; Cell Wall Skeleton; Cytokines; DNA, Bacterial; Glycine; Hum

1989
Plasminogen activator inhibitor is associated with the extracellular matrix of cultured bovine smooth muscle cells.
    The Journal of clinical investigation, 1987, Volume: 80, Issue:4

    Topics: Animals; Cattle; Cells, Cultured; Electrophoresis, Polyacrylamide Gel; Extracellular Matrix; Glycine

1987
8-Azaguanine-resistant melanoma cells in vitro and in vivo.
    Journal of the National Cancer Institute, 1974, Volume: 52, Issue:4

    Topics: Aminopterin; Animals; Azaguanine; Bromodeoxyuridine; Cell Division; Cell Fusion; Cell Line; Drug Res

1974
Altered amino acid concentrations accompanying suppression of malignancy of mouse melanoma cells by 5-bromodeoxyuridine.
    Journal of the National Cancer Institute, 1974, Volume: 52, Issue:1

    Topics: Alanine; Amino Acids; Animals; Asparagine; Bromodeoxyuridine; Cells, Cultured; Glutamates; Glutamine

1974